Transcriptomics Technologies; Techniques Used To Study An Organism's Transcriptome

 

Transcriptomics Technologies

Transcriptomics Technologies are techniques used to study an organism's transcriptome, the sum of all of its RNA transcripts. The information of an organism is recorded in the DNA of its genome and expressed through transcription. Transcriptomics is a comprehensive analysis of whole sets of transcripts for the particular cell, tissue, organ, or whole organism. Transcripts contain all types of RNA molecules, like transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), and other non-coding RNA molecules.

Two biological technologies, such as a sequence-based approach (RNA-seq) and a hybridization-based technique (DNA microarray) are used to study transcriptome. Transcriptomics Technologies simultaneously obtain data from multiple transcripts within a biological sample. Therefore, when a number of biological samples are analyzed, large and complex data sets are generated to study the transcriptome. The term transcriptome can be used to describe the array of mRNA transcripts produced in a particular cell or tissue type.

The Global Transcriptomics Technologies Market Is Estimated To Account For US$ 15,569.1 Mn In Terms Of Value By The End Of 2027.

Transcriptomics Technologies use high-throughput sequencing to identify and characterize a gene expression. They can be used to profile the abundance of genes or to determine the structure of the mRNA transcript, including 5' and 3' ends, start sites, and splice junctions, and to analyze changes in gene expression over time. Transcriptomics technologies have been used to study a wide range of genetic and biological processes, such as cell division, protein synthesis, disease development, as well as to discover novel therapeutic targets.

Transcriptomes of different disease states, tissues, or even single cells are now routinely generated. This explosion in transcriptomics has been driven by the rapid development of new technologies with improved sensitivity and economy. In 2019, Caris Life Sciences announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the company’s MI Transcriptome companion diagnostic (CDx) test. The test is intended to help clinicians identify patients who may benefit from treatment with specific targeted therapies. 


Comments

Popular posts from this blog

Treatment For Eosinophilic Esophagitis Includes Both Pharmaceutical Therapy And Dietary Management

Bio-Identical Hormones Are Synthetic Hormones That Mimic Natural Hormones In The Body

The Art Of Fencing: Unleashing The Graceful Warrior Within